FDA science board supports criticism of agency's BPA stance

November 4, 2008

At an Oct. 31 meeting, the US Food and Drug Administration (FDA)'s full science board unanimously endorsed a subcommittee report that criticized the FDA's stance on bisphenol A (BPA).

At an Oct. 31 meeting, the US Food and Drug Administration (FDA)'s full science board unanimously endorsed a subcommittee report earlier last week that criticized the FDA's stance on bisphenol A (BPA).

As reported by Reuters, the subcomittee had stated that the evidence the FDA used to assess the safety of bisphenol A (BPA) in consumer products is inadequate. The subcommittee claimed that the FDA did not take into account government and university studies that questioned the safety of BPA when the agency released a draft assessment in September.

In the assessment, the FDA defended the position it took in May by stating that, based on the evidence it evaluated, the exposure to BPA in products such as baby bottles is safe. The FDA did add that there are ways consumers can limit their exposure to BPA.